Abstract Details
|
Hesham A. Allam, MD
(Saint Louis University Hospital)
PRESENTER |
Dr. Allam has nothing to disclose. |
| Aws Alawi, MD (Swedish Neuroscience Institute) | No disclosure on file |
| Amer Alshekhlee, MD (SSM Health) | No disclosure on file |
| Nirav Vora, MD | No disclosure on file |
| Sonal Mehta, MD (Tenet Advanced Neuroscience Network) | Dr. Mehta has nothing to disclose. |
| Pablo Villoslada, MD, PhD, FAAN (Hospital del Mar Research Institute) | Dr. Villoslada has received personal compensation for serving as an employee of Attune Neuroscience. Dr. Villoslada has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Accure Therapeutics. Dr. Villoslada has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has stock in Attune Neurosciences. Dr. Villoslada has stock in Bionure Therapeutics. Dr. Villoslada has stock in Spiral Therapeutics. Dr. Villoslada has stock in Adhera Health. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from European Commission. The institution of Dr. Villoslada has received research support from Instituto Salud Carlos III. The institution of Dr. Villoslada has received research support from Focused Ultrasound Foundation and ALS Foundation. The institution of Dr. Villoslada has received research support from Caixa Foundation. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care. |